"New AD Therapies Show Promise In Darker Skin" - Bob Kronemyer
When it comes to treating atopic dermatitis in non-white racial ethnic groups, there are variations in prevalence, genetic factors, and clinical presentation. In addition, delays in treatment and undertreatment can contribute to a higher risk of pigmentary sequelae, including hyperpigmentation and hypopigmentation. ”Fortunately, recently approved therapies show promise in improving outcomes of atopic dermatitis in this patient population,” said Andrew Alexis, MD, chair of the department of dermatology at Mount Sinai St. Luke’s and Mount Sinai West. Dr. Alexis believes that the addition of new therapies specifically targeting key inflammatory pathways in the development of atopic dermatitis should “revolutionize” treatment of the skin disorder in all patients, including patients of color.
- Andrew Alexis, MD, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Chair, Department of Dermatology, Mount Sinai St. Luke’s, Mount Sinai West
Learn more: No link available.
